Merck Will Launch New Proscar Indication During Last Week Of April
Executive Summary
Merck plans to launch a new indication for the benign prostatic hyperplasia therapy Proscar during the American Urology Association annual meeting April 26-May 1
You may also be interested in...
Schering/Merck Ready For Vytorin; Lipid Market Growth Returns
Schering-Plough and Merck are likely to price the Zocor/Zetia combination Vytorin on par with Pfizer's Lipitor, Merck indicated during an April 22 conference call
Merck To Seek Prostate Cancer Claim For Proscar Despite Short Patent Life
Merck intends to file a supplemental NDA for Proscar (finasteride) based on results from the National Cancer Institute's Prostate Cancer Prevention Trial
GSK Dutasteride Launch Set With Added BPH Claims, Avodart Name
GlaxoSmithKline plans to launch its benign prostatic hyperplasia treatment dutasterideunder the brand name Avodart in December